Clinical Trials Browser

Phase 2/3 × disitamab vedotin × 1 year × Clear all

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms